134044-50-1

Basic information

• Product Name: 2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE
• Synonyms: 2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE;imidazo[1,2-a]pyrimidine, 2-(3-nitrophenyl)-;2-(3-Nitro-phenyl)-imidazo[1,2-a] pyrimidine, >96%
• CAS NO: 134044-50-1
• Molecular Formula: C₁₂H₈N₄O₂
• Molecular Weight: 240.22
• Product Categories: pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 134044-50-1.mol

Chemical Properties

• Appearance: /
• Density: 1.448 g/cm³
• Refractive Index: 1.726
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE(134044-50-1)
• EPA Substance Registry System: 2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE(134044-50-1)

Safety Data

• Hazardous Substances Data: 134044-50-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE is used as a building block for the synthesis of biologically active molecules due to its unique chemical structure and potential to contribute to the development of new drugs.
Used in Antiviral Applications:
In the field of antiviral research, 2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE is studied for its potential antiviral properties, which could be harnessed in the creation of new antiviral medications.
Used in Anticancer Applications:
2-(3-NITRO-PHENYL)-IMIDAZO[1,2-A]PYRIMIDINE is also being investigated for its possible anticancer activities, with the aim of identifying its role in the development of novel cancer therapeutics.

InChI:InChI=1/C12H8N4O2/c17-16(18)10-4-1-3-9(7-10)11-8-15-6-2-5-13-12(15)14-11/h1-8H

Upstream product

• 109-12-6 2-aminopyrimidine 
• 2227-64-7 3'-nitro-2-bromoacetophenone 
• 121-89-1 3-Nitroacetophenone 
• 92554-40-0 α-tosyloxy-m-nitroacetophenone 

Downstream Products

• 439108-84-6 3-(imidazo[1,2-a]pyrimidin-2-yl)aniline 

Relevant articles and documents

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

N-(3-heteroarylaryl)-4-arylarylcarboxamides and Analogs as Hedgehog Pathway Inhibitors and Use Thereof

Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D1-D4, Q1, Q2, R5 are defined herein. Compounds having Formul

N-(3-HETEROARYLARYL)-4-ARYLARYLCARBOXAMTDES AND ANALOGS AS HEDGEHOG PATHWAY INHIBITORS AND USE THEREOF

Disclosed are novel N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs thereof, represented by the Formula I: wherein C cyclic group, D1-D4, Q1, Q2, R5 are defined herein. Compounds having Formul

Synthesis and biological evaluation of glucagon-like peptide-1 receptor agonists

In this study, a series of fused-heterocyclic derivatives were systematically designed and synthesized using an efficient route, and evaluated in terms of GLP-1R agonist activity. We employed short synthetic steps and reactions that are tolerant of the presence of various functional groups and suitable for parallel operations to enable the rapid generation of libraries of diverse and structurally complex small molecules. Of the compounds synthesized, 3-(8-chloro-6-(trifluoromethyl)imidazo[1,2-a] pyridin-2-yl)phenyl methanesulfonate (8e) was the most potent agonist with an EC50 of 7.89 μM, and thus is the compound with the greatest potential for application. These findings represent a valuable starting point for the design and discovery of small-molecule GLP-1R agonists that can be administered orally.

A facile [hydroxy(tosyloxy)iodo]benzene mediated synthesis of 2-arylimidazo[1,2-a]pyrimidines and their conversion into 3-bromo-2- arylimidazo[1,2-a]pyrimidines

α-Tosyloxyketone 2, obtained through hypervalent iodine oxidation of enolizable ketones using [hydroxy(tosyloxy)iodo]benzene (HTIB) in acetonitrile, on treatment with 2-aminopyrimidine 3 generates regioselectively 2-arylimidazo[1,2-a]pyrimidine 6 which up

Synthesis of 2-arylimidazo[1,2-a]pyrimidines by the Chichibabin synthesis in ionic liquids

A series of 2-arylimidazo[1,2-a]pyrimidines has been synthesised in excellent yields by the Chichibabin synthesis in room temperature ionic liquids.

Synthesis and antibacterial activity of some imidazo[1,2-a[pyrimidine derivatives

A series of 75 imidazo[1,2-a]pyrimidine derivatives were synthesized. The 'in vitro' antibacterial activity of these compounds and their corresponding α-bromoketones against a variety of gram (+), gram (-) bacteria and Mycobacterium species is reported. Some of the prepared derivatives exhibited potent antimicrobial activity.

Antifungal activity in vitro of some imidazopyrimidine derivatives

In regard to fungicidal activity of imidazole ring found in chemical compounds such as econazole, a series of 42 diversely substituted imidazopyrimidines was synthetized and examined for its antifungal activity in several species.